CNX Therapeutics, a specialty pharmaceutical company, has appointed Erin Federman as a non-executive director, effective from 1 March 2026.
Bringing over two decades of experience to the role, Federman currently works as a strategic advisor and non-executive board member across the life sciences sector.
Federman was previously Marketing & Project Vice President of In-Market Insulins, Diabetes Commercial Unit (Global) at Novo Nordisk, and was VP, Commercial Head of Biologics, Europe at Mylan. She is also a founder and principal of Crestlined Advisory, a company that provides senior advisory services.
Guy Clark, CEO of CNX Therapeutics, said: “Erin’s depth of experience in commercial strategy, market entry and building high-performing organisations in complex international markets makes her exactly the right person to support us as we scale.”
Erin Federman said: “What stands out about CNX is the combination of genuine commercial ambition and a real commitment to patients – not many businesses hold both with equal conviction.”